We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
10
2 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Active, not recruiting
1
10.0%
Completed
Not yet recruiting
Recruiting
7
70.0%
No approval data available
- The SirPAD trial, the world's largest randomized controlled study of sirolimus-coated balloons for peripheral artery disease, enrolled 1,252 patients and demonstrated superior outcomes compared to uncoated balloon angioplasty. - MagicTouch PTA sirolimus-coated balloons reduced major adverse limb events to 8.8% versus 15% with uncoated balloons at one year, showing a risk difference of -4.9%. - The academic all-comers trial included nearly 50% of patients with acute or chronic limb-threatening ischemia, providing robust clinical evidence for hard outcomes. - Results were simultaneously published in the New England Journal of Medicine and presented at ACC 2026, marking a potential turning point for PAD treatment guidelines.